Elevated Fecal Calprotectin Predicts Relapse in Inflammatory Bowel Disease Patients After Stopping TNFα-Blocking Agents

被引：0
|
作者：
Molander, Pauliina
Faerkkilae, Martti A.
Ristimaeki, Ari
Salminen, Kimmo
Kemppainen, Helena
Blomster, Timo
Koskela, Ritva
Jussila, Airi
Rautiainen, Henna
Nissinen, Markku
Haapamaeki, Johanna
Arkkila, Perttu E.
Nieminen, Urpo
Kuisma, Juha
Punkkinen, Jari
Kolho, Kaija-Leena
Mustonen, Harri
Sipponen, Taina
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1054
引用
收藏
页码：S187 / S188
页数：2
相关论文
共 50 条
  • [31] Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission
    Mooiweer, Erik
    Severs, Mirjam
    Schipper, Marguerite E. I.
    Fidder, Herma H.
    Siersema, Peter D.
    Laheij, Robert J. F.
    Oldenburg, Bas
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (01): : 50 - 55
  • [32] Fecal calprotectin: a new marker of inflammatory bowel disease
    Merlotti, Claudia
    Dolci, Alberto
    Scapellato, Luisa
    Panteghini, Mauro
    BIOCHIMICA CLINICA, 2005, 29 (5-6) : 507 - 514
  • [33] Fecal Calprotectin Can Predict Relapse in Inflammatory Bowel Disease Patients in Endoscopic Remission: A Plea for Extreme Deep Remission?
    Mooiweer, Erik
    Severs, Mirjam
    Schipper, Marguerite E.
    Fidder, Herma
    Siersema, Peter D.
    Laheij, Robert
    Oldenburg, Bas
    GASTROENTEROLOGY, 2014, 146 (05) : S233 - S233
  • [34] Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents
    Molander, P.
    Farkkila, M.
    Kemppainen, H.
    Blomster, T.
    Jussila, A.
    Mustonen, H.
    Sipponen, T.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S47 - S47
  • [35] Fecal Calprotectin Is a Useful Marker for Disease Activity in Pediatric Patients with Inflammatory Bowel Disease
    Tomoki Aomatsu
    Atsushi Yoden
    Kyoichi Matsumoto
    Emi Kimura
    Keisuke Inoue
    Akira Andoh
    Hiroshi Tamai
    Digestive Diseases and Sciences, 2011, 56 : 2372 - 2377
  • [36] Fecal Calprotectin Is a Useful Marker for Disease Activity in Pediatric Patients with Inflammatory Bowel Disease
    Aomatsu, Tomoki
    Yoden, Atsushi
    Matsumoto, Kyoichi
    Kimura, Emi
    Inoue, Keisuke
    Andoh, Akira
    Tamai, Hiroshi
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (08) : 2372 - 2377
  • [37] Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients
    Wei-Chen Lin
    Jau-Min Wong
    Chien-Chih Tung
    Ching-Pin Lin
    Jen-Wei Chou
    Horng-Yuan Wang
    Ming-Jium Shieh
    Chin-Hao Chang
    Heng-Hsiu Liu
    Shu-Chen Wei
    World Journal of Gastroenterology, 2015, (48) : 13566 - 13573
  • [38] Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease
    Jusue, Vanesa
    Chaparro, Maria
    Gisbert, Javier P.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (04) : 353 - 359
  • [39] TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
    Altwegg, Romain
    Vincent, Thierry
    MEDIATORS OF INFLAMMATION, 2014, 2014
  • [40] Utility of Fecal Calprotectin Levels for the Diagnosis of Inflammatory Bowel Disease in Patients with Spondyloarthritis
    Espinosa, Maria
    Ramos Giraldez, Consuelo
    Merino, Carolina
    Ruiz Antoran, Belen
    Campos, Jose
    Barbadillo, Carmen
    Godoy, Hilda
    Agudo, Belen
    Gonzalez, Yago
    Luis Andreu, Jose
    Sanz, Jesus
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345